VIVORYON THERAPEUTICS NV (VVY.AS) Fundamental Analysis & Valuation

AMS:VVY • NL00150002Q7

1.42 EUR
+0.04 (+2.75%)
Last: Mar 4, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This VVY.AS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VVY. VVY was compared to 75 industry peers in the Biotechnology industry. VVY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VVY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. VVY.AS Profitability Analysis

1.1 Basic Checks

  • VVY had negative earnings in the past year.
  • In the past year VVY has reported a negative cash flow from operations.
  • In the past 5 years VVY always reported negative net income.
  • In the past 5 years VVY always reported negative operating cash flow.
VVY.AS Yearly Net Income VS EBIT VS OCF VS FCFVVY.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • VVY's Return On Assets of -194.47% is on the low side compared to the rest of the industry. VVY is outperformed by 86.67% of its industry peers.
  • VVY has a worse Return On Equity (-392.42%) than 62.67% of its industry peers.
Industry RankSector Rank
ROA -194.47%
ROE -392.42%
ROIC N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
VVY.AS Yearly ROA, ROE, ROICVVY.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • VVY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VVY.AS Yearly Profit, Operating, Gross MarginsVVY.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. VVY.AS Health Analysis

2.1 Basic Checks

  • VVY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VVY remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for VVY has been increased compared to 5 years ago.
  • Compared to 1 year ago, VVY has a worse debt to assets ratio.
VVY.AS Yearly Shares OutstandingVVY.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
VVY.AS Yearly Total Debt VS Total AssetsVVY.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • VVY has an Altman-Z score of -36.33. This is a bad value and indicates that VVY is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -36.33, VVY is not doing good in the industry: 84.00% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.00 indicates that VVY is not too dependend on debt financing.
  • The Debt to Equity ratio of VVY (0.00) is better than 92.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -36.33
ROIC/WACCN/A
WACC7.44%
VVY.AS Yearly LT Debt VS Equity VS FCFVVY.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 4.04 indicates that VVY has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 4.04, VVY is doing good in the industry, outperforming 77.33% of the companies in the same industry.
  • VVY has a Quick Ratio of 4.04. This indicates that VVY is financially healthy and has no problem in meeting its short term obligations.
  • VVY's Quick ratio of 4.04 is fine compared to the rest of the industry. VVY outperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 4.04
Quick Ratio 4.04
VVY.AS Yearly Current Assets VS Current LiabilitesVVY.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. VVY.AS Growth Analysis

3.1 Past

  • VVY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.00%, which is quite impressive.
  • The Revenue has grown by 100.00% in the past year. This is a very strong growth!
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • VVY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 121.74% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.5%
EPS Next 2Y22.01%
EPS Next 3Y12.69%
EPS Next 5Y121.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VVY.AS Yearly Revenue VS EstimatesVVY.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2023 2029 2030 0 500M 1B 1.5B
VVY.AS Yearly EPS VS EstimatesVVY.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

0

4. VVY.AS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VVY. In the last year negative earnings were reported.
  • Also next year VVY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVY.AS Price Earnings VS Forward Price EarningsVVY.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVY.AS Per share dataVVY.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • VVY's earnings are expected to grow with 12.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.01%
EPS Next 3Y12.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VVY.AS Dividend Analysis

5.1 Amount

  • No dividends for VVY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VVY.AS Fundamentals: All Metrics, Ratios and Statistics

VIVORYON THERAPEUTICS NV

AMS:VVY (3/4/2026, 7:00:00 PM)

1.42

+0.04 (+2.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-04
Earnings (Next)04-27
Inst Owners10.71%
Inst Owner ChangeN/A
Ins Owners10.84%
Ins Owner ChangeN/A
Market Cap42.05M
Revenue(TTM)N/A
Net Income(TTM)-12.48M
Analysts85.71
Price Target5.95 (319.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.82%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)5.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.22
P/tB 17.89
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS0.11
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -194.47%
ROE -392.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.04
Quick Ratio 4.04
Altman-Z -36.33
F-Score2
WACC7.44%
ROIC/WACCN/A
Cap/Depr(3y)105.74%
Cap/Depr(5y)75.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
EPS Next Y49.5%
EPS Next 2Y22.01%
EPS Next 3Y12.69%
EPS Next 5Y121.74%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.68%
EBIT Next 3Y8.27%
EBIT Next 5YN/A
FCF growth 1Y67.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.04%
OCF growth 3YN/A
OCF growth 5YN/A

VIVORYON THERAPEUTICS NV / VVY.AS FAQ

What is the ChartMill fundamental rating of VIVORYON THERAPEUTICS NV (VVY.AS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VVY.AS.


What is the valuation status of VIVORYON THERAPEUTICS NV (VVY.AS) stock?

ChartMill assigns a valuation rating of 0 / 10 to VIVORYON THERAPEUTICS NV (VVY.AS). This can be considered as Overvalued.


Can you provide the profitability details for VIVORYON THERAPEUTICS NV?

VIVORYON THERAPEUTICS NV (VVY.AS) has a profitability rating of 0 / 10.


How financially healthy is VIVORYON THERAPEUTICS NV?

The financial health rating of VIVORYON THERAPEUTICS NV (VVY.AS) is 4 / 10.